| 翻訳と辞書 |
| Juno Therapeutics ： ウィキペディア英語版 |
Juno Therapeutics
Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.〔 The company raised $300 million through private funding and a further $265 million through their IPO.
==Company History==
In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.〔(【引用サイトリンク】title=News Release )〕
In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Junos CD19 directed chimeric antigen receptor T cell candidates.〔(【引用サイトリンク】title=MedImmune, Juno Team Up to Study Cancer Immunotherapy Combo )〕 In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million.〔(【引用サイトリンク】title=Juno Therapeutics Buys Stage Cell Therapeutics for Up-to-$233M )〕 Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas.〔(【引用サイトリンク】title=Juno, Editas Launch Up-to-$737M+ Cancer Therapy Collaboration )〕 In June, the company announced it would acquire X-Body for more than $44 million.〔(【引用サイトリンク】title=Juno Therapeutics Acquires X-Body for $44M+ )〕 In June, the company announced a 10-year partnership with Celgene valued at $1 billion.〔(【引用サイトリンク】title=Celgene Launches $1B Immunotherapy Collaboration with Juno )〕 As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership suprasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.
==Pipeline==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Juno Therapeutics」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|